Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cipla
Covington
Citi
Medtronic
Johnson and Johnson
Cerilliant
Accenture
Colorcon

Generated: May 23, 2018

DrugPatentWatch Database Preview

STALEVO 200 Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Stalevo 200 patents expire, and what generic alternatives are available?

Stalevo 200 is a drug marketed by Orion Pharma and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-six patent family members in forty countries.

The generic ingredient in STALEVO 200 is carbidopa; entacapone; levodopa. There are eighteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the carbidopa; entacapone; levodopa profile page.
Summary for STALEVO 200
International Patents:56
US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: 6
Bulk Api Vendors: 1
Clinical Trials: 16
Formulation / Manufacturing:see details
DailyMed Link:STALEVO 200 at DailyMed
Drug patent expirations by year for STALEVO 200

US Patents and Regulatory Information for STALEVO 200

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orion Pharma STALEVO 200 carbidopa; entacapone; levodopa TABLET;ORAL 021485-004 Aug 2, 2007 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Orion Pharma STALEVO 200 carbidopa; entacapone; levodopa TABLET;ORAL 021485-004 Aug 2, 2007 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for STALEVO 200

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Orion Pharma STALEVO 200 carbidopa; entacapone; levodopa TABLET;ORAL 021485-004 Aug 2, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Orion Pharma STALEVO 200 carbidopa; entacapone; levodopa TABLET;ORAL 021485-004 Aug 2, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Orion Pharma STALEVO 200 carbidopa; entacapone; levodopa TABLET;ORAL 021485-004 Aug 2, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for STALEVO 200
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 50 mg/200 mg/200 mg ➤ Subscribe 2008-08-28

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
QuintilesIMS
Teva
Cantor Fitzgerald
US Army
Citi
US Department of Justice
Colorcon
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.